Publication: Efficacy and safety of ruxolitinib in patients with myelofibrosis: A retrospective and multicenter experience in Turkey
dc.contributor.author | Soyer, Nur | |
dc.contributor.author | Ali, Ridvan | |
dc.contributor.author | Turgut, Mehmet | |
dc.contributor.author | Haznedaroglu, Ibrahim C. | |
dc.contributor.author | Yilmaz, Fergun | |
dc.contributor.author | Aydogdu, Ismet | |
dc.contributor.author | Karakus, Volkan | |
dc.contributor.author | Ozgur, Gokhan | |
dc.contributor.author | Kis, Cem | |
dc.contributor.author | Ceran, Funda | |
dc.contributor.author | Ilhan, Gul | |
dc.contributor.author | Ozkan, Melda | |
dc.contributor.author | Aslaner, Muzeyyen | |
dc.contributor.author | Ince, Idris | |
dc.contributor.author | Yavasoglu, Irfan | |
dc.contributor.author | Gediz, Fusun | |
dc.contributor.author | Sonmez, Mehmet | |
dc.contributor.author | Guvenc, Birol | |
dc.contributor.author | Ozet, Gulsum | |
dc.contributor.author | Kaya, Emin | |
dc.contributor.author | Vural, Filiz | |
dc.contributor.author | Tobu, Mahmut | |
dc.contributor.author | Durusoy, Raika | |
dc.contributor.buuauthor | Pir, Ali | |
dc.contributor.buuauthor | KAYA, PİR ALİ | |
dc.contributor.buuauthor | Vural, Filiz | |
dc.contributor.buuauthor | Şahin, Fahri | |
dc.contributor.buuauthor | Saydam, Guray | |
dc.contributor.department | Bursa Uludağ Üniversitesi/Tıp Fakültesi/Hematoloji Anabilim Dalı. | |
dc.contributor.orcid | 0000-0001-5118-6894 | |
dc.contributor.orcid | 0000-0001-9178-2850 | |
dc.contributor.orcid | 0000-0001-7423-7180 | |
dc.contributor.orcid | 0000-0002-7798-4349 | |
dc.contributor.orcid | 0000-0001-6621-3138 | |
dc.contributor.orcid | 0000-0002-2176-4371 | |
dc.contributor.orcid | 0000-0001-8605-8497 | |
dc.contributor.orcid | 0000-0003-1041-8462 | |
dc.contributor.researcherid | W-3827-2017 | |
dc.contributor.researcherid | ABH-5764-2020 | |
dc.contributor.researcherid | AAB-7711-2022 | |
dc.contributor.researcherid | JYO-9281-2024 | |
dc.contributor.researcherid | W-2951-2017 | |
dc.contributor.researcherid | HRC-6282-2023 | |
dc.contributor.researcherid | W-7916-2019 | |
dc.contributor.researcherid | B-7408-2009 | |
dc.contributor.researcherid | A-4238-2018 | |
dc.date.accessioned | 2024-06-28T10:57:16Z | |
dc.date.available | 2024-06-28T10:57:16Z | |
dc.date.issued | 2021-01-01 | |
dc.description.abstract | Background/aim: The aim of this study is to assess the efficacy and safety of ruxolitinib in patients with myelofibrosis. Materials and methods: From 15 centers, 176 patients (53.4% male, 46.6% female) were retrospectively evaluated. Results: The median age at ruxolitinib initiation was 62 (28-87) and 100 (56.8%) of all were diagnosed as PMF. Constitutional symptoms were observed in 84.7%. The median initiation dose of ruxolitinib was 30 mg (10-40). Dose change was made in 69 (39.2%) patients. Forty seven (35.6%) and 20 (15.2%) of 132 patients had hematological and nonhematological adverse events, respectively. The mean spleen sizes before and after ruxolitinib treatment were 219.67 +/- 46.79 mm versus 199.49 +/- 40.95 mm, respectively (p < 0.001). There was no correlation between baseline features and subsequent spleen response. Overall survival at 1-year was 89.5% and the median follow up was 10 (1-55) months. We could not show any relationship between survival and reduction in spleen size (p = 0.73). Conclusion: We found ruxolitinib to be safe, well tolerated, and effective in real-life clinical practice in Turkey. Ruxolitinib dose titration can provide better responses in terms of not only clinical benefit but also for long term of ruxolitinib treatment. | |
dc.identifier.doi | 10.3906/sag-1812-70 | |
dc.identifier.endpage | 1042 | |
dc.identifier.issn | 1300-0144 | |
dc.identifier.issue | 3 | |
dc.identifier.startpage | 1033 | |
dc.identifier.uri | https://doi.org/10.3906/sag-1812-70 | |
dc.identifier.uri | https://hdl.handle.net/11452/42582 | |
dc.identifier.volume | 51 | |
dc.identifier.wos | 000668244900016 | |
dc.indexed.wos | WOS.SCI | |
dc.language.iso | en | |
dc.publisher | Tubitak Scientific & Technological Research Council Turkey | |
dc.relation.journal | Turkish Journal Of Medical Sciences | |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.subject | International working group | |
dc.subject | World-health-organization | |
dc.subject | Available therapy | |
dc.subject | Japanese patients | |
dc.subject | Myeloproliferative neoplasms | |
dc.subject | Myeloid neoplasms | |
dc.subject | Comfort-ii | |
dc.subject | Open-label | |
dc.subject | Classification | |
dc.subject | Diagnosis | |
dc.subject | Myelofibrosis | |
dc.subject | Treatment | |
dc.subject | Survival | |
dc.subject | Ruxolitinib | |
dc.subject | Adverse events | |
dc.subject | Science & technology | |
dc.subject | Life sciences & biomedicine | |
dc.subject | Medicine, general & internal | |
dc.subject | General & internal medicine | |
dc.title | Efficacy and safety of ruxolitinib in patients with myelofibrosis: A retrospective and multicenter experience in Turkey | |
dc.type | Article | |
dspace.entity.type | Publication | |
relation.isAuthorOfPublication | bf1461a7-9902-4912-8b57-79e19851530a | |
relation.isAuthorOfPublication.latestForDiscovery | bf1461a7-9902-4912-8b57-79e19851530a |
Files
Original bundle
1 - 1 of 1